ライフサイエンスコーパス: necrolysis

1 ith Stevens-Johnson syndrome/toxic epidermal necrolysis).

2 tevens-Johnson syndrome, and toxic epidermal necrolysis.

3 oRNA biomarker/mechanism for toxic epidermal necrolysis.

4 tevens-Johnson syndrome, and toxic epidermal necrolysis.

5 tevens-Johnson syndrome, and toxic epidermal necrolysis.

6 Stevens-Johnson syndrome and toxic epidermal necrolysis.

7 Stevens-Johnson syndrome or toxic epidermal necrolysis.

8 , the national referral center for epidermal necrolysis.

9 Stevens-Johnson syndrome and toxic epidermal necrolysis.

10 to Stevens-Johnson syndrome/toxic epidermal necrolysis.

11 Stevens-Johnson Syndrome and toxic epidermal necrolysis.

12 Stevens-Johnson syndrome and toxic epidermal necrolysis.

13 tevens-Johnson syndrome, and toxic epidermal necrolysis), 2 months (drug eruption and eczematous derm

14 ith Stevens-Johnson syndrome/toxic epidermal necrolysis, 86 with drug reaction with eosinophilia and

15 to the pathogenesis of ICI-induced epidermal necrolysis and provide potential therapeutic targets for

16 es the epidermal necrosis in toxic epidermal necrolysis and provides a potential target for therapeut

17 Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe cutan

18 rge burst of nitric oxide in toxic epidermal necrolysis and Stevens-Johnson syndrome may cause the ep

19 progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to mode

20 the pathogenesis of eczema, toxic epidermal necrolysis, and drug-induced skin eruptions.

21 ng from pneumococcal sepsis, toxic epidermal necrolysis, and renal failure) occurred at doses exceedi

22 Stevens-Johnson syndrome and toxic epidermal necrolysis are severe adverse cutaneous drug reactions c

23 and Stevens-Johnson syndrome/toxic epidermal necrolysis, can be severe and result in a diverse set of

24 Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic

25 In-hospital mortality for epidermal necrolysis (EN) has been well-characterized, but less is

26 s for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosis and are

27 The incidence of epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS

28 multiforme (IC(025) = 1.03), toxic epidermal necrolysis (IC(025) = 0.95), Stevens-Johnson syndrome (I

29 Stevens-Johnson syndrome and toxic epidermal necrolysis in specific Asian populations (including Han

30 Epidermal necrolysis is a severe cutaneous adverse reaction in whi

31 er Stevens-Johnson syndrome, toxic epidermal necrolysis, or aplastic anemia.

32 for Stevens-Johnson syndrome/toxic epidermal necrolysis over a 14-year period were included.

33 our Stevens-Johnson syndrome/toxic epidermal necrolysis patients and is associated with a poor outcom

34 of Stevens-Johnson syndrome/toxic epidermal necrolysis patients at higher risk of intubation could h

35 A teenage survivor of toxic epidermal necrolysis presented with faint but diffuse dyschromia c

36 Stevens-Johnson syndrome and toxic epidermal necrolysis remain among the most devastating of acute co

37 e Algorithm for Drug Causality for Epidermal Necrolysis, respectively.

38 Algorithm for Drug Causality for Epidermal Necrolysis scoring was discordant in 28 cases, labeling

39 everity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN), was recently found to overestimate

40 of severity was the Score of Toxic Epidermal Necrolysis (SCORTEN), which ranges from 0 to 7, with 7 t

41 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia

42 se, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia

43 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) are part of a disease continuum of

44 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse reactio

45 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug r

46 Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) group, whereas glaucoma was found n

47 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is a rare but life-threatening cuta

48 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe hypersensitivity reacti

49 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is known to cause multiple end-orga

50 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), although a detailed description is

51 as Stevens-Johnson syndrome, toxic epidermal necrolysis (SJS/TEN), and drug reaction with eosinophili

52 as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hindering continuous ICI therapy.

53 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), which are the most severe types of

54 ing Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

55 reatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivi

56 of PubMed using the keywords toxic epidermal necrolysis, Stevens-Johnson syndrome, photo-distributed,

57 the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found

58 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among carbamazepine users, especially i

59 Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are

60 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening disorders.

61 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous adve

62 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening condition

63 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening mucocutan

64 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life-threateni

65 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug reactions associated wi

66 evens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the pathologic role

67 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cause diffuse epidermal detachment and

68 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been infrequently reported since t

69 We report a rare case of toxic epidermal necrolysis (TEN) in a 10-year-old boy with no significan

70 Toxic epidermal necrolysis (TEN) is a fatal drug-induced skin reaction t

71 Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction invol

72 ents with chronic ocular SJS/toxic epidermal necrolysis (TEN) were included in the study.

73 vens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and graft-versus-host disease (GVHD) a

74 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life-threatening.

75 vens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and system

76 vens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and sys

77 vens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or SJS/TEN was performed.

78 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), varies across studies.

79 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

80 s-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

81 commonly used prognostic score in epidermal necrolysis, the Severity-of-Illness Score for Toxic Epid

82 ospital mortality in patients with epidermal necrolysis to study the incremental prognostic value of

83 e Algorithm for Drug Causality for Epidermal Necrolysis was highly probable or probable in all cases.

84 Stevens-Johnson syndrome/toxic epidermal necrolysis was the most common indication (49.1%), follo

85 A total of 196 patients with epidermal necrolysis were recruited, 4 (2%) of whom were excluded

86 the placebo group had fatal toxic epidermal necrolysis with concurrent Pseudomonas aeruginosa bacter